Open drug discovery for the Zika virus

Sean Ekins, Daniel Mietchen, Megan Coffee, Thomas P. Stratton, Joel S. Freundlich, Lucio Freitas-Junior, Eugene Muratov, Jair Siqueira-Neto, Antony J. Williams, Carolina Andrade

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The Zika virus (ZIKV) outbreak in the Americas has caused global concern that we may be on the brink of a healthcare crisis. The lack of research on ZIKV in the over 60 years that we have known about it has left us with little in the way of starting points for drug discovery. Our response can build on previous efforts with virus outbreaks and lean heavily on work done on other flaviviruses such as dengue virus. We provide some suggestions of what might be possible and propose an open drug discovery effort that mobilizes global science efforts and provides leadership, which thus far has been lacking. We also provide a listing of potential resources and molecules that could be prioritized for testing as in vitro assays for ZIKV are developed. We propose also that in order to incentivize drug discovery, a neglected disease priority review voucher should be available to those who successfully develop an FDA approved treatment. Learning from the response to the ZIKV, the approaches to drug discovery used and the success and failures will be critical for future infectious disease outbreaks.

Original languageEnglish (US)
Article number150
JournalF1000Research
Volume5
DOIs
StatePublished - Jan 1 2016

Fingerprint

Drug Discovery
Viruses
Disease Outbreaks
Neglected Diseases
Flavivirus
Dengue Virus
Learning
Delivery of Health Care
Zika Virus
Assays
Research
Molecules
Testing

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Ekins, S., Mietchen, D., Coffee, M., Stratton, T. P., Freundlich, J. S., Freitas-Junior, L., ... Andrade, C. (2016). Open drug discovery for the Zika virus. F1000Research, 5, [150]. https://doi.org/10.12688/f1000research.8013.1
Ekins, Sean ; Mietchen, Daniel ; Coffee, Megan ; Stratton, Thomas P. ; Freundlich, Joel S. ; Freitas-Junior, Lucio ; Muratov, Eugene ; Siqueira-Neto, Jair ; Williams, Antony J. ; Andrade, Carolina. / Open drug discovery for the Zika virus. In: F1000Research. 2016 ; Vol. 5.
@article{e41875e8248a41a19f416ba20f62481a,
title = "Open drug discovery for the Zika virus",
abstract = "The Zika virus (ZIKV) outbreak in the Americas has caused global concern that we may be on the brink of a healthcare crisis. The lack of research on ZIKV in the over 60 years that we have known about it has left us with little in the way of starting points for drug discovery. Our response can build on previous efforts with virus outbreaks and lean heavily on work done on other flaviviruses such as dengue virus. We provide some suggestions of what might be possible and propose an open drug discovery effort that mobilizes global science efforts and provides leadership, which thus far has been lacking. We also provide a listing of potential resources and molecules that could be prioritized for testing as in vitro assays for ZIKV are developed. We propose also that in order to incentivize drug discovery, a neglected disease priority review voucher should be available to those who successfully develop an FDA approved treatment. Learning from the response to the ZIKV, the approaches to drug discovery used and the success and failures will be critical for future infectious disease outbreaks.",
author = "Sean Ekins and Daniel Mietchen and Megan Coffee and Stratton, {Thomas P.} and Freundlich, {Joel S.} and Lucio Freitas-Junior and Eugene Muratov and Jair Siqueira-Neto and Williams, {Antony J.} and Carolina Andrade",
year = "2016",
month = "1",
day = "1",
doi = "10.12688/f1000research.8013.1",
language = "English (US)",
volume = "5",
journal = "F1000Research",
issn = "2046-1402",
publisher = "F1000 Research Ltd.",

}

Ekins, S, Mietchen, D, Coffee, M, Stratton, TP, Freundlich, JS, Freitas-Junior, L, Muratov, E, Siqueira-Neto, J, Williams, AJ & Andrade, C 2016, 'Open drug discovery for the Zika virus', F1000Research, vol. 5, 150. https://doi.org/10.12688/f1000research.8013.1

Open drug discovery for the Zika virus. / Ekins, Sean; Mietchen, Daniel; Coffee, Megan; Stratton, Thomas P.; Freundlich, Joel S.; Freitas-Junior, Lucio; Muratov, Eugene; Siqueira-Neto, Jair; Williams, Antony J.; Andrade, Carolina.

In: F1000Research, Vol. 5, 150, 01.01.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Open drug discovery for the Zika virus

AU - Ekins, Sean

AU - Mietchen, Daniel

AU - Coffee, Megan

AU - Stratton, Thomas P.

AU - Freundlich, Joel S.

AU - Freitas-Junior, Lucio

AU - Muratov, Eugene

AU - Siqueira-Neto, Jair

AU - Williams, Antony J.

AU - Andrade, Carolina

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The Zika virus (ZIKV) outbreak in the Americas has caused global concern that we may be on the brink of a healthcare crisis. The lack of research on ZIKV in the over 60 years that we have known about it has left us with little in the way of starting points for drug discovery. Our response can build on previous efforts with virus outbreaks and lean heavily on work done on other flaviviruses such as dengue virus. We provide some suggestions of what might be possible and propose an open drug discovery effort that mobilizes global science efforts and provides leadership, which thus far has been lacking. We also provide a listing of potential resources and molecules that could be prioritized for testing as in vitro assays for ZIKV are developed. We propose also that in order to incentivize drug discovery, a neglected disease priority review voucher should be available to those who successfully develop an FDA approved treatment. Learning from the response to the ZIKV, the approaches to drug discovery used and the success and failures will be critical for future infectious disease outbreaks.

AB - The Zika virus (ZIKV) outbreak in the Americas has caused global concern that we may be on the brink of a healthcare crisis. The lack of research on ZIKV in the over 60 years that we have known about it has left us with little in the way of starting points for drug discovery. Our response can build on previous efforts with virus outbreaks and lean heavily on work done on other flaviviruses such as dengue virus. We provide some suggestions of what might be possible and propose an open drug discovery effort that mobilizes global science efforts and provides leadership, which thus far has been lacking. We also provide a listing of potential resources and molecules that could be prioritized for testing as in vitro assays for ZIKV are developed. We propose also that in order to incentivize drug discovery, a neglected disease priority review voucher should be available to those who successfully develop an FDA approved treatment. Learning from the response to the ZIKV, the approaches to drug discovery used and the success and failures will be critical for future infectious disease outbreaks.

UR - http://www.scopus.com/inward/record.url?scp=84978471430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978471430&partnerID=8YFLogxK

U2 - 10.12688/f1000research.8013.1

DO - 10.12688/f1000research.8013.1

M3 - Article

AN - SCOPUS:84978471430

VL - 5

JO - F1000Research

JF - F1000Research

SN - 2046-1402

M1 - 150

ER -

Ekins S, Mietchen D, Coffee M, Stratton TP, Freundlich JS, Freitas-Junior L et al. Open drug discovery for the Zika virus. F1000Research. 2016 Jan 1;5. 150. https://doi.org/10.12688/f1000research.8013.1